3認識銀屑病與代謝綜合征二者關係的臨床意義
大部分皮膚科醫生和銀屑病患者對銀屑病與代謝綜合征的關係認識不足 [25]。
銀屑病的系統治療對代謝有負面作用。 環孢素可以引起高血壓、胰島素抵抗、血脂異常, 高尿酸血症等心血管疾病是環孢素的絕對禁忌證, 阿維 A 會引起高三醯甘油血症和高膽固醇血症。 因此, 在給予銀屑病患者系統用藥前應對其代謝情況進行監測 [27]。
心血管疾病是銀屑病患者不良預後的最主要原因 [28]。 因此, 銀屑病的治療目標不僅是消除皮損,
4結語
銀屑病與代謝綜合征及心血管疾病等多種疾病相關。 促炎性因數和脂肪細胞因數在代謝綜合征、心血管疾病等銀屑病合併症的發病中起重要作用。 其機制可能是銀屑病形成的系統性炎性因數引起胰島素抵抗, 進而形成代謝障礙。 因此, 不能簡單地認為銀屑病是一種皮膚疾病, 而是一種系統性炎症性疾病。 在臨床實踐中,
參考文獻
1 Schreve BS, Boehncke WH. Psoriasis, in Psoriatic Arthritis and Psoriasis[M]. Berlin :Springer, 2016 :129-137.
2 Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome [J]. Lancet, 2010, 375(9710):181-183.
3 Zindanci I, Albayrak O, Kavala M, et al. Prevalence of metabolic syndrome in patients with psoriasis[J/OL]. https ://www.hindawi.
com/journals/tswj/2012/312463.
4 Miller IM, Ellervik C, Zarchi K, et al. The association of metabolic syndrome and psoriasis :a population- and hospital-based cross-sectional study[J]. J Eur Acad Dermatol Venereol, 2015, 29(3): 490-497.
5 Danielsen K, Wilsgaard T, Olsen AO, et al. Elevated odds of metabolic syndrome in psoriasis :a population-based study of age and sex differences[J]. Br J Dermatol, 2015, 172(2):419-427.
6 Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome :a systematic review and meta-analysis of observational studies[J]. J Am Acad Dermatol, 2013, 68(4): 654-662.
7 Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis :a population-based study in the United Kingdom[J]. J Invest Dermatol, 2012, 132(3 Pt 1):556-562.
8 Naldi L, Conti A, Cazzaniga S, et al. Diet and physical exercise in psoriasis :a randomized controlled trial[J]. Br J Dermatol, 2014, 170(3):634-642.
9 Reid CT, Tobin AM, Ahern T, et al. Liraglutide in combination with acitretin for severe recalcitrant psoriasis[J]. Br J Dermatol, 2013,
169(1):230-231.
10 Singh S, Bhansali A. Randomized placebo control study of insulin sensitizers(Metformin and Pioglitazone)in psoriasis patients with metabolic syndrome(Topical Treatment Cohort)[J]. BMC Dermatol, 2016, 16(1):12.
11 Boehncke WH, Boehncke S, Tobin AM, et al. The‘psoriatic march’:a concept of how severe psoriasis may drive cardiovascular comorbidity[J]. Exp Dermatol, 2011, 20(4):303-307.
12 Uysal S, Yilmaz FM, Karatoprak K, et al. The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis[J]. Eur Rev Med Pharmacol Sci, 2014, 18(22):3453-3458.
13 Shlyankevich J, Mehta NN, Krueger JG, et al. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities[J]. Am J Med, 2014, 127(12):1148-1153.
14 Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity[J]. Mediators Inflamm, 2005, 2005(5):273-279.
variants and colorectal cancer risk :the Multiethnic Cohort and PAGE
studies[J]. Gut, 2011, 60(12):1703-1711.
15 Chen L, Chen R. Mechanisms Linking Inflammation to Insulin Resistance[J/OL]. https ://www.hindawi.com/journals/ ije/2015/508409.
16 Ndumele CE, Pradhan AD, Ridker PM. Interrelationships between inflammation, C-reactive protein, and insulin resistance[J]. J Cardiometab Syndr, 2006, 1(3):190-196.
17 Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation[J]. Hypertension, 2005, 45(5):828-833.
18 Hojlund K. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance[J]. Dan Med J, 2014, 61(7):B4890.
19 Wolk K, Sabat R. Adipokines in psoriasis :An important link between skin inflammation and metabolic alterations[J]. Rev Endocr Metab Disord, 2016, 17(3):305-317.
20 Triantafyllou GA, Paschou SA, Mantzoros CS. Leptin and Hormones : Energy Homeostasis[J]. Endocrinol Metab Clin North Am, 2016, 45(3):633-645.
21 Zhu KJ, Zhang C, Li M, et al. Leptin levels in patients with psoriasis : a meta-analysis[J]. Clin Exp Dermatol, 2013, 38(5):478-483.
22 Mattioli B, Straface E, Matarrese P, et al. Leptin as an immunological adjuvant :enhanced migratory and CD8+ T cell stimulatory capacity of human dendritic cells exposed to leptin[J]. FASEB J, 2008, 22
23 Orlova EG, Shirshev SV, Loginova OA. Leptin and ghrelin regulate dendritic cell maturation and dendritic cell induction of regulatory T-cells[J]. Dokl Biol Sci, 2015, 462 :171-174.
24 Xue K, Liu H, Jian Q, et al. Leptin induces secretion of pro-inflammatory cytokines by human keratinocytes in vitro--a possible reason for increased severity of psoriasis in patients with a high body mass index[J]. Exp Dermatol, 2013, 22(6):406-410.
25 Aurangabadkar SJ. Comorbidities in psoriasis[J]. Indian J Dermatol Venereol Leprol, 2013, 79 Suppl 7 :S10-S17.
26 Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities[J]. Dermatol Clin, 2015, 33(1):41-55.
27 Voiculescu VM, Lupu M, Papagheorghe L, et al. Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications[J]. J Med Life, 2014, 7(4):468-471.
28 Mosca S, Gargiulo P, Balato N, et al. Ischemic cardiovascular involvement in psoriasis :a systematic review[J]. Int J Cardiol, 2015, 178 :191-199.
29 Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities :focus on TNF inhibitors[J]. Am J Clin Dermatol, 2014, 15(1):45-50.
30 Peluso I, Palmery M. The relationship between body weight and inflammation :Lesson from anti-TNF-α antibody therapy[J]. Hum Immunol, 2016, 77(1):47-53.
31 Jellema P, van der Windt DA, Bruinvels DJ, et al. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care : systematic review and meta-analysis[J]. Bmj, 2010, 340 :c1269.
32 Cubiella J, Salve M, Díaz-Ondina M, et al. Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients :comparison with Nice and SIGN referral criteria[J]. Colorectal Dis, 2014, 16(8):O273-O282.
33 Adelstein BA, Macaskill P, Turner RM, et al. The value of age and medical history for predicting colorectal cancer and adenomas in people referred for colonoscopy[J]. BMC Gastroenterol, 2011, 11 :97.
34 Marshall T, Lancashire R, Sharp D, et al. The diagnostic performance of scoring systems to identify symptomatic colorectal cancer compared to current referral guidance[J]. Gut, 2011, 60(9): 1242-1248